Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and ?-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor ? inhibitor–associated dermatitis - 09/01/20
Abstract |
Background |
T helper (Th) type 17 and Th2 cells mediate psoriasis and eczema, respectively. Some dermatoses exhibit overlapping clinicopathologic features, and their immunopathology is relatively unexplored.
Objective |
To determine whether Th17 and Th2 subsets and interleukin (IL) 36 and β-defensin 2 (BD-2) markers of IL-17 signaling expression can discriminate between biopsy samples of psoriasis and eczematous/spongiotic dermatitis and to use those markers to immunophenotype cases with clinicopathologic overlap.
Methods |
A retrospective study was performed on biopsy samples of psoriasis, eczema/spongiotic dermatitis, sebopsoriasis, tumor necrosis factor α inhibitor–associated psoriasiform dermatitis, and ambiguous cases diagnosed as spongiotic psoriasiform dermatitis. Dual CD4/GATA3 and CD4/RORC, IL-36, and BD-2 immunohistochemistry was performed.
Results |
IL-36 and BD-2 were strongly expressed in biopsy samples of psoriasis compared with eczema/spongiotic dermatitis. No significant differences were observed in the percentages of Th2 and Th17 cells between disease types. Strong expression of IL-36 and BD-2 was observed in a subset of spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor–associated psoriasiform dermatitis biopsy samples.
Limitations |
This was an exploratory study with a small sample size. No multiple testing adjustment was done. Clinical follow-up was limited.
Conclusions |
In cases with clinicopathologic overlap between psoriasis and spongiotic dermatitis, IL-36, and to a lesser extent BD-2, may be used to assess for a psoriasis-like/IL-17 phenotype, which could inform therapeutic clinical decisions.
Le texte complet de cet article est disponible en PDF.Key words : β-defensin 2, eczema, IL-17, IL-36, psoriasis, sebopsoriasis, seborrheic dermatitis, spongiotic dermatitis, spongiotic psoriasiform dermatitis, Th17, Th2, TNF-α inhibitor
Abbreviations used : BD-2, IL, pDC, SD/PSO, STAT, TNF, TNFAID
Plan
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 82 - N° 2
P. 430-439 - février 2020 Retour au numéro
Article précédent
- Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins
- Emily Stamell Ruiz, Shlomo A. Koyfman, Syril Keena T. Que, Jason Kass, Chrysalyne D. Schmults
- Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review
- Franchesca D. Choi, Christina N. Kraus, Ashley N. Elsensohn, Sama K. Carley, Larisa M. Lehmer, Rebecca T. Nguyen, Kenneth G. Linden, Jessica Shiu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?